Last reviewed · How we verify
L19TNF and TMZ
TNF-alpha inhibitor
TNF-alpha inhibitor Used for Glioblastoma.
At a glance
| Generic name | L19TNF and TMZ |
|---|---|
| Sponsor | Philogen S.p.A. |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
L19TNF is a TNF-alpha inhibitor that works by binding to TNF-alpha and preventing it from interacting with its receptors, thereby reducing inflammation and immune response.
Approved indications
- Glioblastoma
Common side effects
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma (PHASE2)
- Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L19TNF and TMZ CI brief — competitive landscape report
- L19TNF and TMZ updates RSS · CI watch RSS
- Philogen S.p.A. portfolio CI